Aura Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 76.41 million compared to USD 58.76 million a year ago. Basic loss per share from continuing operations was USD 1.93 compared to USD 1.96 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.37 USD | -2.51% | +3.66% | -16.82% |
05-29 | Transcript : Aura Biosciences, Inc. - Special Call | |
05-09 | Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.82% | 375M | |
+16.59% | 45.51B | |
-9.89% | 38.52B | |
+38.08% | 38.13B | |
+27.12% | 30.74B | |
-8.64% | 26.03B | |
+11.81% | 25.92B | |
+45.08% | 14.13B | |
+32.85% | 12.73B | |
-7.19% | 11.29B |
- Stock Market
- Equities
- AURA Stock
- News Aura Biosciences, Inc.
- Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023